In conclusion, this study demonstrated that use of pen-administered low-dose dasiglucagon, a novel, ready-to-use glucagon analogue, to treat and prevent non-severe hypoglycaemia during free-living conditions was safe, fast and efficacious while significantly reducing the total daily carbohydrate intake and yielding high treatment satisfaction. Here, GCG is linked to Hypoglycemia.